CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-01 | KARABELAS ARGERIS N Director | Option exercise 10b5-1 | +10,000 | $3.76 | $38K | 21,286 |
| 2024-08-01 | KARABELAS ARGERIS N Director | Option exercise 10b5-1 | +100 | $12.74 | $1K | 21,386 |
| 2024-08-01 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −9,600 | $13.45 | $129K | 11,786 |
| 2024-08-01 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −400 | $14.59 | $6K | 11,386 |
| 2024-08-01 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −100 | $15.00 | $2K | 11,286 |
| 2024-08-01 | KARABELAS ARGERIS N Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −100 | 1,400 | ||
| 2024-08-01 | KARABELAS ARGERIS N Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −10,000 | 20,000 | ||
| 2024-08-01 | Simpson Curran Chief Executive Officer | Sale 10b5-1 | −100 | $15.00 | $2K | 170,037 |
| 2024-08-01 | Danos Olivier Chief Scientific Officer | Grant or award | +58,867 | 185,083 | ||
| 2024-07-29 | KARABELAS ARGERIS N Director | Option exercise 10b5-1 | +11,000 | $12.74 | $140K | 22,286 |
| 2024-07-29 | KARABELAS ARGERIS N Director | Sale 10b5-1 | −11,000 | $15.05 | $165K | 11,286 |
| 2024-07-29 | KARABELAS ARGERIS N Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −11,000 | 1,500 | ||
| 2024-07-29 | Simpson Curran Chief Executive Officer | Sale 10b5-1 | −9,648 | $15.04 | $145K | 170,137 |
| 2024-07-25 | Mills Kenneth T. Director | Option exercise 10b5-1 | +15,369 | $3.76 | $58K | 423,404 |
| 2024-07-25 | Mills Kenneth T. Director | Sale 10b5-1 | −15,369 | $13.96 | $215K | 408,035 |
| 2024-07-25 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −15,369 | 51,354 | ||
| 2024-07-24 | Mills Kenneth T. Director | Option exercise 10b5-1 | +12,221 | $3.76 | $46K | 420,256 |
| 2024-07-24 | Mills Kenneth T. Director | Sale 10b5-1 | −12,221 | $13.78 | $168K | 408,035 |
| 2024-07-24 | Mills Kenneth T. Director | Option exercise · Stock Options (Right to Buy) 10b5-1 | −12,221 | 66,723 | ||
| 2024-07-17 | Mills Kenneth T. Director | Option exercise 10b5-1 | +2,210 | $3.76 | $8K | 410,245 |
Page 7 of 11 · 216 trades